Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
American Association of Individual Investors5d
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. Read more about ZLAB stock here.
63,909 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) during the fourth quarter, HoldingsChannel reports. The firm purchased 63,909 ...
Yahoo Finance4d
Zai Lab Limited (ZLAB)
We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing ...
Scotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price ...
Investing5d
Zai Lab Ltd (ZLAB)
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Zai Lab (NASDAQ:ZLAB) Ltd on Thursday, setting a price target ...
Sarepta Therapeutics (SRPT) Gets a Hold from Scotiabank
In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report), with a price ...
Scotiabank Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price ...